智通财经网·2025-08-20 11:17Core Viewpoint - CanSino Biologics (06185) reported a revenue of approximately 374 million yuan for the first half of 2025, representing a year-on-year increase of 31.1% [1] Financial Performance - The company's R&D expenditure decreased by 20.5% to approximately 148 million yuan [1] - The net loss attributable to the owners narrowed to 13.485 million yuan, a year-on-year reduction of 94.02% [1] - The loss per share was 0.05 yuan [1] Product Development - The company continued to advance the commercialization of its meningococcal conjugate vaccine, with sales revenue of approximately 364 million yuan, an increase of 38.4% compared to the same period last year [1] - The vaccine has successfully penetrated the mid-to-high-end vaccine market in China, with increasing market penetration [1] R&D Efficiency - The reduction in R&D expenditure was primarily due to the company's focus on integrating R&D resources and leveraging potential synergies among different pipelines [1] - This strategy has enhanced R&D efficiency while also lowering costs, allowing the company to concentrate resources on high-potential R&D projects [1]